在患有急性严重性结肠炎的孕妇中Mirikizumab的有效性:一个病例报告
Marco Murgiano1, Angelo Del Gaudio2,3, Pierluigi Puca2,3
1Department of Medicine and Translational Surgery, Università Cattolica del Sacro Cuore, Rome, Italy - marcomurgiano1@gmail.com.
Minerva gastroenterology
|January 9, 2026
概括
米里基祖马布作为急性严重性结肠炎 (ASUC) 孕妇的救援疗法具有前景. 本案例研究详细介绍了它在耐皮质类固醇耐药患者的成功使用,强调了怀孕期间潜在的安全性和有效性.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 产科 产科 产科 产科 产科
背景情况:
- 急性严重性结肠炎 (ASUC) 是一种需要及时干预的危急状况.
- 米里基祖马布 (Mirikizumab) 是一种抗23单克隆抗体,已被批准用于中度至重度的性结肠炎,但缺乏ASUC和怀孕的证据.
- 皮质类固醇耐药性疾病和胆管切除术在怀孕期间存在重大风险.
研究的目的:
- 报告Mirikizumab作为救援疗法的第一例,用于ASUC的孕妇患者.
- 为了评估Mirikizumab在这种特定的临床场景中的疗效和安全性.
主要方法:
- 一名30岁的孕妇有耐火性胰腺炎史,在怀孕18周时接受了Mirikizumab作为ASUC的救援疗法.
- 监测了临床和内镜反应.
- 评估了产科和新生儿结局.
主要成果:
- 患者在第一剂Mirikizumab剂量后一天内经历了快速的临床改善.
- 临床缓解维持了一个月后启动与改善的炎症标志物.
- 一个健康的早产婴儿在怀孕35周和4天后通过剖腹产分娩.
结论:
- 米里基祖马布可能是一个可行的救援治疗选择,孕妇与皮质类固醇耐药ASUC.
- 这一案例表明了潜在的疗效和安全性,但进一步的研究是必不可少的.
- 需要更多的研究来证实Mirikizumab在ASUC中的作用及其在怀孕中的安全性.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
425
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
425
Inflammatory Bowel Disease IV: Pharmacological Management
471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
471
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478
Inflammatory Bowel Disease I: Ulcerative Colitis
882
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
882


